• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Product › Details

clinical research

	Next higher product group	pharma services

Record changed: 2019-12-19

Advertisement

More documents for clinical research

• [1] KCR S.A.. (1/13/20). "Press Release: KCR Announces New Chief Commercial Officer. Bryan Katz Joins KCR’s Growing Executive Team to Take Over as Head of Commercial Strategy and Global Partnerships". Boston, MA....
• [2] CureVac AG. (1/7/20). "Press Release: CureVac Announces Positive Results in Low Dose – 1 µg – Rabies Vaccine Clinical Phase 1 Study". Tübingen & Boston, MA....
• [3] Bicycle Therapeutics plc. (1/7/20). "Press Release: Bicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle Immuno-oncology Candidate, BT7401". London, Cambridge & Boston, MA....
• [4] MorphoSys AG. (12/30/19). "Press Release: MorphoSys Announces Submission of Biologics License Application for Tafasitamab in r/r DLBCL to the FDA". Planegg....
• [5] Boehringer Ingelheim. (12/18/19). "Press Release: Boehringer Ingelheim Discontinues Development of BI 1467335 for NASH". Ingelheim & Sydney....
• [6] KCR S.A.. (12/18/19). "Press Release: KCR Adopts Veeva Vault Clinical Suite". Boston, MA....
• [7] GlaxoSmithKline plc. (12/16/19). "Press Release: Pivotal DREAMM-2 Study Demonstrated a Clinically Meaningful Overall Response Rate with Belantamab Mafodotin (GSK2857916) for Patients with relapsed/refractory Multiple Myeloma". London....
• [8] Sphingotec GmbH. (12/16/19). "Press Release: Sphingotec’s Proprietary Biomarker bio-ADM Detects Residual Congestion in Patients with Heart Failure". Hennigsdorf....
• [9] Boehringer Ingelheim. (12/13/19). "Press Release: Boehringer Ingelheim and Lilly Provide Update on Empagliflozin Phase III Exercise Ability Studies in Chronic Heart Failure". Ingelheim & Indianapolis, IN....
• [10] Genmab A/S. (12/13/19). "Press Release: CHMP Issues Positive Opinion Recommending Darzalex (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma". Copenhagen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2020. Made in Germany.